Dabrafenib in combination with trametinib for treating BRAF V600 mutation-positive anaplastic thyroid cancer
Agency for Care Effectiveness (ACE)
Record ID 32018002578
English
Details
Project Status:
Completed
Year Published:
2022
URL for published report:
https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidances/details/dabrafenib-in-combination-with-trametinib-for-treating-braf-v600-mutation-positive-anaplastic-thyroid-cancer
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Singapore
MeSH Terms
- Thyroid Neoplasms
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
- Thyroid Carcinoma, Anaplastic
- Protein Kinase Inhibitors
Contact
Organisation Name:
Agency for Care Effectiveness (ACE)
Contact Address:
Ministry of Health, College of Medicine Building, 16 College Road, Singapore 169854
Contact Name:
ACE_HTA@moh.gov.sg
Contact Email:
ACE_HTA@moh.gov.sg
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.